Cargando…
Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease
BACKGROUND AND AIMS: Whereas immediate postoperative treatment has shown effectiveness in reducing endoscopic postoperative recurrence [POR], evidence regarding the clinical benefit is limited. We compared rates of clinical POR in Crohn’s disease [CD] patients receiving immediate prophylactic treatm...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069621/ https://www.ncbi.nlm.nih.gov/pubmed/36124739 http://dx.doi.org/10.1093/ecco-jcc/jjac139 |
_version_ | 1785018883741057024 |
---|---|
author | Joustra, Vincent van Sabben, Joris van der does de Willebois, Eline Duijvestein, Marjolijn de Boer, Nanne Jansen, Jeroen van der Bilt, Jarmila Lameris, Wytze Bemelman, Willem Buskens, Christianne D’Haens, Geert |
author_facet | Joustra, Vincent van Sabben, Joris van der does de Willebois, Eline Duijvestein, Marjolijn de Boer, Nanne Jansen, Jeroen van der Bilt, Jarmila Lameris, Wytze Bemelman, Willem Buskens, Christianne D’Haens, Geert |
author_sort | Joustra, Vincent |
collection | PubMed |
description | BACKGROUND AND AIMS: Whereas immediate postoperative treatment has shown effectiveness in reducing endoscopic postoperative recurrence [POR], evidence regarding the clinical benefit is limited. We compared rates of clinical POR in Crohn’s disease [CD] patients receiving immediate prophylactic treatment with rates in patients receiving endoscopy-driven treatment. METHODS: We retrospectively collected data from 376 consecutive CD patients who underwent an ileocaecal resection with anastomosis between 2007 and 2018 with at least 3 years of follow-up at three sites. Subsequently, high- and low-risk patients categorised by established guidelines, who underwent endoscopy within 12 months postoperatively, were grouped according to a prophylactic- or endoscopy-driven approach and compared for incidence and time till endoscopic and clinical POR. RESULTS: Prophylactic treatment reduced rates of and time till endoscopic POR within 1 year in high-risk (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.27-0.86, p = 0.04, number needed to treat [NNT] = 5) but not low-risk [HR 0.90, 95% CI 0.32-2.56, p = 0.85] patients. Conversely, no significant differences in clinical POR within 3 years between prophylactic- and endoscopy-driven low-risk [HR 1.17, 95% CI 0.41-3.29, p = 0.75] and high-risk patients were observed [HR 1.06, 95% CI 0.63-1.79, p = 0.82, NNT = 22]. However, a large numerical albeit not statistical significant difference in 3-year clinical POR [28.6% vs. 62.5%, p = 0.11] in a subset of high-risk patients with three or more ECCO-defined risk factors was observed, indicating a cumulative effect of having multiple risk factors. CONCLUSION: Our observations favour step-up treatment guided by early endoscopic evaluation with prophylactic treatment reserved for carefully selected high-risk patients, in order to avoid potential overtreatment of a significant number of patients. |
format | Online Article Text |
id | pubmed-10069621 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-100696212023-04-04 Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease Joustra, Vincent van Sabben, Joris van der does de Willebois, Eline Duijvestein, Marjolijn de Boer, Nanne Jansen, Jeroen van der Bilt, Jarmila Lameris, Wytze Bemelman, Willem Buskens, Christianne D’Haens, Geert J Crohns Colitis Original Articles BACKGROUND AND AIMS: Whereas immediate postoperative treatment has shown effectiveness in reducing endoscopic postoperative recurrence [POR], evidence regarding the clinical benefit is limited. We compared rates of clinical POR in Crohn’s disease [CD] patients receiving immediate prophylactic treatment with rates in patients receiving endoscopy-driven treatment. METHODS: We retrospectively collected data from 376 consecutive CD patients who underwent an ileocaecal resection with anastomosis between 2007 and 2018 with at least 3 years of follow-up at three sites. Subsequently, high- and low-risk patients categorised by established guidelines, who underwent endoscopy within 12 months postoperatively, were grouped according to a prophylactic- or endoscopy-driven approach and compared for incidence and time till endoscopic and clinical POR. RESULTS: Prophylactic treatment reduced rates of and time till endoscopic POR within 1 year in high-risk (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.27-0.86, p = 0.04, number needed to treat [NNT] = 5) but not low-risk [HR 0.90, 95% CI 0.32-2.56, p = 0.85] patients. Conversely, no significant differences in clinical POR within 3 years between prophylactic- and endoscopy-driven low-risk [HR 1.17, 95% CI 0.41-3.29, p = 0.75] and high-risk patients were observed [HR 1.06, 95% CI 0.63-1.79, p = 0.82, NNT = 22]. However, a large numerical albeit not statistical significant difference in 3-year clinical POR [28.6% vs. 62.5%, p = 0.11] in a subset of high-risk patients with three or more ECCO-defined risk factors was observed, indicating a cumulative effect of having multiple risk factors. CONCLUSION: Our observations favour step-up treatment guided by early endoscopic evaluation with prophylactic treatment reserved for carefully selected high-risk patients, in order to avoid potential overtreatment of a significant number of patients. Oxford University Press 2022-09-17 /pmc/articles/PMC10069621/ /pubmed/36124739 http://dx.doi.org/10.1093/ecco-jcc/jjac139 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Joustra, Vincent van Sabben, Joris van der does de Willebois, Eline Duijvestein, Marjolijn de Boer, Nanne Jansen, Jeroen van der Bilt, Jarmila Lameris, Wytze Bemelman, Willem Buskens, Christianne D’Haens, Geert Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title | Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title_full | Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title_fullStr | Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title_full_unstemmed | Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title_short | Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn’s Disease |
title_sort | benefit of risk-stratified prophylactic treatment on clinical outcome in postoperative crohn’s disease |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10069621/ https://www.ncbi.nlm.nih.gov/pubmed/36124739 http://dx.doi.org/10.1093/ecco-jcc/jjac139 |
work_keys_str_mv | AT joustravincent benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT vansabbenjoris benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT vanderdoesdewilleboiseline benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT duijvesteinmarjolijn benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT deboernanne benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT jansenjeroen benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT vanderbiltjarmila benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT lameriswytze benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT bemelmanwillem benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT buskenschristianne benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease AT dhaensgeert benefitofriskstratifiedprophylactictreatmentonclinicaloutcomeinpostoperativecrohnsdisease |